LYELHealthcareSmall-Cap
Lyell Immunopharma, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Lyell Immunopharma, Inc. (LYEL), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are LYEL insiders buying or selling?
Lyell Immunopharma, Inc. insiders reported 8 open-market buys ($25.7M) and 28 sells ($598.2K) across 36 Form 4 filings — a net buying position of $25.1M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 20, 2026)
Total Form 4 filings
36
SEC EDGAR
Insider filers
13
Insider buys (8)
$25.7M
Insider sells (28)
$598.2K
Insider sentiment
Net buyingNet insider flow of $25.1M in net buying.
Recent LYEL insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 20, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | Sale | 10 | $13.70 | $137 |
| Jul 18, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | Sale | 10 | $13.73 | $137.3 |
| Jun 15, 2026 | Lynn Seely | President and CEO | Sale | 388 | $18.91 | $7.3K |
| Jun 15, 2026 | Gary K. Lee | Chief Scientific Officer | Sale | 130 | $18.92 | $2.5K |
| Jun 15, 2026 | Stephen J. Hill | Chief Operating Officer | Sale | 89 | $18.92 | $1.7K |
| Jun 15, 2026 | Veronica Sanchez Bulis | VP, Corporate Controller | Sale | 217 | $18.91 | $4.1K |
| Jun 11, 2026 | David Shook | Chief Medical Officer | Sale | 2.0K | $12.64 | $25.0K |
| Mar 9, 2026 | ARCH Venture Partners IX, LLC | 10% Owner | Purchase | 488.1K | $25.61 | $12.5M |
| Mar 9, 2026 | Keith Crandell | 10% Owner | Purchase | 488.1K | $25.61 | $12.5M |
| Feb 13, 2026 | Lynn Seely | President and CEO | Sale | 7.5K | $23.39 | $174.4K |
| Feb 13, 2026 | Stephen J. Hill | Chief Operating Officer | Sale | 1.2K | $23.39 | $28.9K |
| Feb 13, 2026 | Gary K. Lee | Chief Scientific Officer | Sale | 1.7K | $23.39 | $39.1K |
| Feb 12, 2026 | Stephen J. Hill | Chief Operating Officer | Sale | 109 | $23.12 | $2.5K |
| Feb 12, 2026 | Gary K. Lee | Chief Scientific Officer | Sale | 147 | $23.12 | $3.4K |
| Feb 12, 2026 | Lynn Seely | President and CEO | Sale | 438 | $23.12 | $10.1K |
| Feb 12, 2026 | Veronica Sanchez Bulis | VP, Corporate Controller | Sale | 254 | $23.12 | $5.9K |
| Jan 6, 2026 | Veronica Sanchez Bulis | VP, Corporate Controller | Sale | 2.1K | $35.80 | $74.2K |
| Nov 13, 2025 | Lynn Seely | President and CEO | Sale | 412 | $16.11 | $6.6K |
| Nov 13, 2025 | Veronica Sanchez Bulis | VP, Corporate Controller | Sale | 239 | $16.10 | $3.8K |
| Nov 13, 2025 | Gary K. Lee | Chief Scientific Officer | Sale | 138 | $16.16 | $2.2K |
| Nov 13, 2025 | Stephen J. Hill | Chief Operating Officer | Sale | 95 | $16.12 | $1.5K |
| Aug 22, 2025 | Lynn Seely | President and CEO | Sale | 7.3K | $10.54 | $76.5K |
| Aug 22, 2025 | Stephen J. Hill | Chief Operating Officer | Sale | 1.0K | $10.54 | $10.6K |
| Aug 22, 2025 | Charles W. Newton | Chief Financial Officer | Sale | 1.5K | $10.54 | $15.3K |
| Aug 22, 2025 | Gary K. Lee | Chief Scientific Officer | Sale | 1.5K | $10.54 | $15.3K |
Showing the 25 most recent of 36 Form 4 filings for Lyell Immunopharma, Inc..
Most active LYEL insiders
- Lynn Seely7 filings
- Gary K. Lee6 filings
- Stephen J. Hill6 filings
- Veronica Sanchez Bulis4 filings
- Charles W. Newton3 filings
Ask anything about LYEL insider activity
Use Trabud's AI agent to query Lyell Immunopharma, Inc.'s Form 4 history in plain English — "Show me LYEL CEO purchases this year" or compare it against any other ticker.
Open the AI agentLYEL insider trading FAQ
Are Lyell Immunopharma, Inc. insiders buying or selling?
Across 36 SEC Form 4 filings, Lyell Immunopharma, Inc. (LYEL) insiders reported 8 open-market purchases totaling $25.7M and 28 sales totaling $598.2K. That is a net buying position of $25.1M.
How many insiders trade LYEL stock?
13 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Lyell Immunopharma, Inc.. The most recent filing was accepted on Jul 20, 2026.
Where does Trabud get LYEL insider trading data?
All LYEL insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.